证券记录 · 已归档季度
VRDN
Viridian Therapeutics, Inc. · Healthcare · Biotechnology
13被追踪持有人
+2Δ持有人
10.47M持有股份
$141.20M报告持仓市值
+2新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +18.2% ·
股份流向 -3.8% ·
净新建仓位 +15.4%
— 公式
持股分散化 — 持有人增多，合计持仓比例缩小
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q1 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | -12 | 71.65M | $1.32B | +6 | −18 |
| Q1 2026 | 88 | +7 | 66.96M | $1.32B | +11 | −5 |
| Q4 2025 | 82 | +2 | 62.58M | $1.95B | +4 | −1 |
| Q3 2025 | 16 | -1 | 34.97M | $754.70M | — | −1 |
| Q2 2025 | 14 | -2 | 33.44M | $467.46M | — | −2 |
| Q1 2025 | 13 | +2 | 10.47M | $141.20M | +2 | — |
| Q4 2024 | 11 | -2 | 10.88M | $208.63M | — | −2 |
| Q3 2024 | 12 | +3 | 5.78M | $131.57M | +3 | — |
| Q2 2024 | 9 | — | 3.15M | $40.97M | — | — |
持有人 · Q1 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (被动) | 2.87M | -18.6% | $38.63M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (被动) | 1.72M | +3.7% | $23.20M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (被动) | 1.72M | +3.7% | $23.20M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 1.69M | +27.2% | $22.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.69M | +27.2% | $22.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 1.11M | -33.3% | $15.02M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Marshall Wace ✦ | 1.08M | 新增 | $14.61M | 0.0% | New | 1 | SEC ↗ |
| 8 | Fisher Asset Management ✦ | 537.02K | +3.7% | $7.24M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 320.30K | -13.7% | $4.32M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Millennium Management ✦ | 297.97K | -18.6% | $4.02M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Wellington Management ✦ | 249.17K | +11.0% | $3.36M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Wellington Management ✦ | 249.17K | +11.0% | $3.36M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Wellington Management ✦ | 249.17K | +11.0% | $3.36M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Wellington Management ✦ | 249.17K | +11.0% | $3.36M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 222.40K | -47.6% | $3.00M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | Point72 Asset Management ✦ | 204.70K | 新增 | $2.76M | 0.0% | New | 1 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 88.55K | -75.3% | $1.19M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 88.55K | -75.3% | $1.19M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 81.38K | -81.6% | $1.10M | 0.0% | ▼ Trim | 3 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| Marshall Wace | $14.61M | 0.0% |
| Point72 Asset Management | $2.76M | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 225 持有人, 111.32M 股份, $2.12B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Aug 19
Tousignant Jennifer
Officer · 4.21K 股 · $103,194
Aug 19
Tousignant Jennifer
Officer · 10.00K 股 · $245,000
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 20
SC 13G — Point72 Asset Management, L.P.
Aug 14
SC 13G/A — Paradigm Biocapital Advisors LP
Aug 14
SC 13G/A — Kynam Capital Management, LP
Aug 14
SC 13G/A — Deep Track Capital, LP
Aug 14
SC 13G — PRICE T ROWE ASSOCIATES INC /MD/
Aug 07
SC 13G — STATE STREET CORP
Jun 26
SC 13G — Paradigm Biocapital Advisors LP
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q1 2025 ·
方法论 ·
通过API获取此数据